Fennec Pharmaceuticals Inc. (FENC)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 9.14 |
| Open | 9.05 |
| Bid | 9.14 x 400 |
| Ask | 9.21 x 200 |
| Day's range | 9.01 - 9.32 |
| 52-week range | 6.30 - 11.92 |
| Volume | |
| Avg. volume | 135,780 |
| Market cap | 249.568M |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.60 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.33 |
Simply Wall St.Those who invested in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago are up 136%
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
GuruFocus.comInsider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC)
Fennec Pharmaceuticals Inc (NASDAQ:FENC), a biopharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients, has reported a significant insider sell transaction.
GuruFocus.comChief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC)
Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals Inc (NASDAQ:FENC), has sold 13,975 shares of the company on March 26, 2024, according to a recent SEC Filing.
© 2024 Yahoo. All rights reserved.